8031.T (8031.T)

$18.08T
Market Cap
20.2
P/E Ratio
0.48
Beta
1.88%
Dividend Yield
Piotroski 6/9Altman Z 3.0 Gray ZoneROIC−WACC +0.8%

Quantitative Summary

Deterministic

Financial health is average: Piotroski 6/9, Altman Z 3.0.

Generated deterministically from quant metrics and financial statements. Not a recommendation.

Algorithmic Teardown

AI-Generated

The capital allocation efficiency for this entity presents a modest positive spread, with Return on Invested Capital at 8.1% exceeding the Weighted Average Cost of Capital by only 0.8%, suggesting limited value creation relative to financing costs. This dynamic is further illuminated by the DuPont components: while revenue growth of 10.0% indicates top-line momentum, profitability remains constrained with a net margin of 6.1% and gross margin of 8.8%. The Piotroski F-Score of 6/9 signals moderate fundamental strength without indicating robust financial distress or exceptional quality, whereas an Altman Z-Score of 3.0 places the company in a grey zone between safety and potential bankruptcy risk, warranting caution regarding liquidity buffers despite the absence of explicit leverage metrics in the provided dataset.

Valuation analysis reveals a significant disparity between current market pricing and intrinsic value estimates derived from discounted cash flow modeling. The stock trades at a forward P/E multiple of 20.2x, which appears elevated when weighed against an implied fair value of $5737; however, without historical sector averages or prior year multiples to establish a relative context, the premium cannot be definitively characterized as inefficient. The DCF model's output suggests that current market prices may not fully reflect long-term cash flow potential at the stated discount rate, yet the wide gap between implied equity value and trading levels introduces uncertainty regarding future growth assumptions embedded in the valuation framework.

Risk assessment highlights a divergence between operational momentum and credit safety margins. While revenue expansion supports a Piotroski score above the median threshold for financial health, the Altman Z-Score of 3.0 acts as a counterweight to this optimism, implying that earnings volatility or asset structure could expose shareholders to heightened downside risk if economic conditions deteriorate. The combination of thin operating spreads and moderate solvency metrics suggests that any future multiple expansion would need to be decoupled from fundamental deterioration in profitability ratios to justify the current price-to-earnings ratio.

Generated by LLM from quantitative data inputs. May contain inaccuracies. Not investment advice.

DCF Sandbox

Interactive

Sensitivity Matrix

TG ↓ / WACC →6%7.3%9.3%
2%$6447$4622$3026
3%$8630$5737$3537
4%$12995$7537$4242

Center = base case. Green = >10% upside, Red = >10% downside vs .

Pre-computed DCF: WACC=7.3%, terminal growth 3%. Fair value $5737 (+0.0%). Not investment advice.

Price Chart with Moving Averages

Loading chart...
SMA 50 SMA 200

Quant Health Deep Dive

6/9
Piotroski F-Score
Average — mixed operational signals
3.0
Altman Z-Score
Grey Zone — between 1.8 and 3.0 thresholds. Thresholds: >3 safe, 1.8–3 grey, <1.8 distress.

Profitability & Value Creation

8.8%
Gross Margin
6.1%
Net Margin
8.1%
ROIC
7.3%
WACC
ROIC − WACC Spread: +0.8%— Positive spread.
+10.0%
Revenue Growth (YoY)
-15.4%
Earnings Growth (YoY)
671.4B
Free Cash Flow
41%
FCF Payout Ratio

✅ Conservative payout — room for dividend increases.

Balance Sheet Health

1.17x
Debt / Equity
1.56x
Current Ratio
6.5x
Interest Coverage
1.9x
Net Debt / EBITDA
3.17%
FCF Yield
1.7T
EBITDA

Earnings Surprise History

Q4
✗ Miss
Est: $95.02
Act: $85.85
-9.6%
Q3
✗ Miss
Est: $67.30
Act: $66.68
-0.9%
Q2
✓ Beat
Est: $57.35
Act: $80.73
+40.8%
Q1
✗ Miss
Est: $75.31
Act: $65.67
-12.8%

EPS estimates vs actuals for the most recent reported quarters. Source: yfinance.

Underwater (Drawdown from Peak)

How far below the all-time high the price has been over time. Deeper = more pain for holders.

Loading drawdown chart...

Rolling 60-Day Beta vs S&P 500 (VOO)

How the stock's sensitivity to market moves changes over time. β > 1 = more volatile than the market.

Loading beta chart...
Rolling Beta Market (β = 1.0)

Fundamentals

21.7
Forward P/E
PEG Ratio
2.16
Price/Book
8M
Avg Volume
$6675.00
52W High
$2468.00
52W Low
52W Range Position

8031.T Capital Efficiency

How efficiently does 8031.T convert operating profits into free cash? The FCF Conversion ratio measures the gap between accounting earnings and real cash generation.

Free Cash Flow
$671.4B
EBITDA
$1655.0B
FCF Conversion
41%
Reinvestment Rate
59%
41% of EBITDA → Free Cash
0% (cash burn)25% (low)50% (efficient)100% (pure cash)
ROIC
8.1%
ROIC − WACC Spread
0.8%

8031.T converts 41% of its EBITDA into free cash flow, a healthy conversion rate indicating efficient capital management — the business generates substantial cash after reinvestment. The 59% reinvestment rate signals aggressive capacity expansion. The positive ROIC-WACC spread of 0.8% confirms that reinvested capital creates shareholder value.

Capital efficiency = Free Cash Flow ÷ EBITDA. Reinvestment = (EBITDA − FCF) ÷ EBITDA. Metrics from latest annual filings. Not investment advice.

Compare 8031.T to Peers

Quant metrics computed deterministically from financial statements and price data. Updated: N/A.

SecuritiesDB provides programmatic data aggregation for informational purposes only. None of the metrics, summaries, or algorithmic flags constitute a recommendation to buy or sell any security.